An **Antiphospholipid Syndrome (APS) Panel** is a comprehensive blood test used to diagnose an autoimmune disorder characterized by inappropriate blood clot formation and pregnancy complications.
The panel evaluates three primary autoantibodies: **Lupus Anticoagulant (LA)**, **Anti-Cardiolipin (aCL) IgG/IgM**, and **Anti-Beta-2 Glycoprotein I (aβ2GPI) IgG/IgM**. These antibodies mistakenly target normal proteins bound to phospholipids in cell membranes.
A positive panel helps clinicians confirm an APS diagnosis, assessing the risk for deep vein thrombosis (DVT), arterial strokes, or recurrent miscarriages. To fulfill formal diagnostic criteria, positive results must be confirmed by retesting at least 12 weeks later.

An **Any Lumps and Bumps Test** evaluation refers to a clinical diagnostic approach used to investigate unexplained swellings, masses, or cutaneous nodules on the body.
Rather than a single blood test, this assessment typically combines physical examination with imaging modalities like **ultrasound**, **MRI**, or a **fine-needle aspiration (FNA) biopsy** to determine the characteristics of the lump.
The primary utility is differentiating between benign conditions (such as lipomas, sebaceous cysts, or swollen lymph nodes) and malignant tumors. Identifying the exact nature of the tissue growth ensures accurate staging, patient reassurance, and the timely implementation of appropriate medical or surgical intervention strategies.